ANL Reiterated by HC Wainwright & Co. -- Price Target Maintained

Adlai Nortye ANL Analyst Rating Update - September 8, 2026 On September 8, 2026, analyst Joseph Pantginis from HC Wainwright & Co. has reiterated his rating for Adlai Nortye (ANL) as a "Buy," while maintaining the price target at $20.00. This confirmation follows a consistent outlook from previous assessments. Key valuation metric: Price-to-Sales (P/S) ratio is approximately 2.73, compared to its historical median of ~2.7x. GF Score™: 8/100, indicating a relatively low overall score in terms of financial health and growth potential. Insider activity shows a sell value of $164,621 over the past three months, suggesting caution among insiders. What's Behind the Analyst Rating? The reaffirmation of the "Buy" rating by Pantginis reflects a strong belief in Adlai Nortye's potential to deliver value to investors, particularly as the company continues to develop its innovative cancer therapies. This rating is significant as it underscores the analyst's confidence in the company's strategic direction and its ability to navigate the complexities of the biotechnology sector. Adlai Nortye Ltd is a clinical-stage company focused on discovering and developing cancer therapies. With a market capitalization of approximately $1.006 billion, it operates within the healthcare sector, specifically in biotechnology. The company is advancing a robust pipeline of drug candidates aimed at addressing significant unmet needs in cancer treatment, particularly through RAS-targeting therapies and next-generation cancer immunotherapies. How Is ANL Valued? Currently, GF Value™ data is not available for Adlai Nortye, making it challenging to evaluate its intrinsic value directly. However, the Price-to-Sales (P/S) ratio stands at approximately 2.73, which is in line with its historical median, indicating that the stock may be fairly valued based on sales metrics. Given the company's unprofitability and cash-flow-negative status, traditional earnings-based valuation methods such as the P/E ratio are not applicable in this context. For more detailed information, visit the ANL stock page. What Does ANL's GF Score™ Tell Us? The GF Score™ measures a company's financial strength, profitability, growth potential, valuation, and momentum. Adlai Nortye's score of 8/100 indicates significant challenges, particularly in profitability and growth. The company ranks particularly low in profitability, which is a critical area of concern for investors. Metric Rating GF Score™ 8 Financial Strength 4 Profitability 1 The strengths of Adlai Nortye lie in its financial strength ranking, which, although low, is better than its profitability rank. The company's inability to generate profits and its cash-flow-negative status are significant weaknesses that investors should consider. For further insights, check the ANL stock page. What Are Gurus and Insiders Doing with ANL? Currently, two gurus hold shares of Adlai Nortye, with two adding to their positions and none trimming their holdings in recent quarters. This indicates a cautious optimism among institutional investors. Additionally, insider activity has shown a sell value of $164,621 over the past three months, which may suggest that insiders are taking profits or reducing exposure, a signal that investors should monitor closely. What This Means for Investors Given the current analyst rating of "Buy" and the price target of $20.00, investors might view Adlai Nortye as a potential opportunity, albeit with caution due to its low GF Score™ and financial challenges. The insider selling activity could be a red flag, indicating that while analysts remain optimistic, there are underlying concerns that investors should consider before making any investment decisions. For more details, visit the ANL stock page. Frequently Asked Questions What is ANL's GF Score™? ANL's GF Score™ is 8/100, indicating significant challenges in financial health and growth potential. Is ANL overvalued or undervalued? With a Price-to-Sales ratio of approximately 2.73, ANL appears to be fairly valued based on its historical sales metrics, but its unprofitability raises concerns. What do analysts recommend for ANL? Analysts currently recommend a "Buy" rating for ANL, with a price target of $20.00, reflecting confidence in the company's future despite its financial challenges.